Introduction: Drugs are at the origin of around 10% of the cases of vasculitis involving the small vessels. Recent cases report vasculitis related to the administration of nonsteroidal antiinflammatory selective inhibitors of cyclo-oxygenase 2.
Case: Vasculitis associated with ketoprofen appeared in a 76 year-old man: the symptoms disappeared when treatment stopped. A few weeks later, during treatment with rofecoxib, a relapse appeared, including purpura. The diagnosis of rofecoxib-induced cutaneous vasculitis was confirmed by regression of all symptoms when treatment stopped.
Discussion: Coxibs, like other nonsteroidal antiinflammatory drugs, may cause vasculitis, at an as-yet undetermined frequency.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0755-4982(05)84101-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the analgesic dose of intravenous ketamine versus ketorolac in patients with chest trauma: A randomized double-blind clinical trial.
Acad Emerg Med
December 2024
Fellowship in Emergency Trauma, Montreal General Hospital, McGill University, Montreal, Quebec, Canada.
Background: Pain management is a critical part of treatment in patients with chest trauma. Opioids and nonsteroidal anti-inflammatory drugs have been the most commonly used medications. However, their side effects have drawn attention to other medications.
View Article and Find Full Text PDFGastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
United European Gastroenterol J
December 2024
The Sheba Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel.
Background: Gastrointestinal perforations have been reported in a small number of rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors in clinical trials. However, large-scale postmarketing data repositories are needed to further investigate this potentially rare but serious adverse event.
Methods: A retrospective, pharmacovigilance study of the FDA adverse event reporting system (July 2014 to September 2023) assessing the reporting of gastrointestinal perforations following JAK inhibitors compared to biological disease-modifying antirheumatic drugs (bDMARDs) in RA patients.
Application of Nanomaterials Targeting Immune Cells in the Treatment of Chronic Inflammation.
Int J Nanomedicine
December 2024
Department of Oral Implantology, Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China.
Article Synopsis
- Chronic inflammation is linked to various diseases and is characterized by prolonged immune cell activation, resulting in tissue damage.
- Despite the effectiveness of current anti-inflammatory medications, they often have side effects due to non-specific targeting.
- Nanoparticle drug delivery shows promise for targeted therapy in inflammation, but improvements are needed to specifically target different immune cell types for enhanced therapeutic effects.
Role of Strong Opioids in an Effective Discharge for Lower-Limb Large Joint Arthroplasty Patients: A Patient-Based Analysis.
Cureus
November 2024
Orthopaedics and Trauma, Russells Hall Hospital, Dudley, GBR.
Background/objective: Adequate postoperative analgesics are an essential element in the recovery and rehabilitation of large joint lower-limb arthroplasty patients in their acute postoperative phase. In this study, we will establish that strong opioids like morphine should be included as postoperative analgesics to improve patient satisfaction. Material: This retrospective cross-sectional study was conducted in the Arthroplasty Ward, Trauma, and Orthopaedics Department in a district general hospital of the United Kingdom.
View Article and Find Full Text PDFOsteoarthritis: An integrative overview from pathogenesis to management.
Malays J Pathol
December 2024
Universiti Kebangsaan Malaysia, 43600 Bangi, Faculty of Medicine, Department of Pharmacology, 56000 Cheras, Kuala Lumpur, Malaysia.
Osteoarthritis (OA) is a prevalent degenerative joint disease characterised by cartilage and subchondral bone breakdown, impacting millions worldwide. This review provides an overview of the complex aetiology of OA, integrating biochemical, mechanical, and genetic factors. It also emphasises a multifaceted management approach, combining non-pharmacological, pharmacological, and surgical treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!